Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort.

Akihito Kawazoe Noboru Yamamoto Naotoshi Sugimoto Hiasto Kawakami Takashi Oshima Kensei Yamaguchi Kaori Hino Motohiro Hirao Yukinori Kurokawa Takeshi Kawakami Masahiro Tsuda Hiroki Hara Shota Kaname Daiko Matsuoka Yohei Otake Keisuke Yasuda Takao Takase Shuya Takashima Taro Semba Kei Muro

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Promising antitumor activity was observed with E7389-LF in combination with nivolumab in patients with gastric cancer, and no new safety signals were observed, compared with either monotherapy.

Keyphrases

phase ii study
open label
locally advanced
phase ii
drug delivery
clinical trial
metastatic breast cancer
combination therapy
squamous cell carcinoma
placebo controlled
phase iii
rectal cancer